How to Get Rezdiffra (Resmetirom) in Florida

Rezdiffra FDA Approval and Clinical Background

Resmetirom is the first FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH. The FDA granted accelerated approval in March 2024 based on histological endpoints from the MAESTRO-NASH phase 3 trial 1.

MAESTRO-NASH Trial Results

In MAESTRO-NASH (N=966), resmetirom 80 mg and 100 mg achieved MASH resolution without worsening fibrosis in 25.9% and 29.9% of patients respectively at 52 weeks, compared with 9.7% for placebo 1. A fibrosis improvement endpoint (reduction by at least one stage with no worsening of NAFLD activity score) was met by 24.2% on the 80 mg dose and 25.9% on the 100 mg dose versus 14.2% on placebo 2.

Mechanism of Action

Resmetirom is a liver-directed thyroid hormone receptor beta (THR-beta) agonist. The FDA label describes reduced intrahepatic triglycerides and changes in lipid markers as pharmacodynamic effects, while still requiring clinical monitoring for hepatotoxicity, gallbladder events, and drug interactions 2.

Who Qualifies for Rezdiffra in Florida

The FDA label indicates Rezdiffra, in conjunction with diet and exercise, for adults with noncirrhotic MASH/NASH with moderate-to-advanced liver fibrosis consistent with stages F2 to F3 2. Florida prescribers should document that the patient fits those criteria before prescribing.

Diagnostic Requirements

FibroScan, magnetic resonance elastography (MRE), blood-based scores, and liver biopsy can all contribute to staging, but cutoffs vary by test, population, and clinical context. EASL guidance supports non-invasive tests for fibrosis risk stratification, and the AASLD 2023 practice guidance recommends non-invasive fibrosis assessment as part of routine NAFLD/MASLD care 4, 5.

Weight-Based Dosing

Patients weighing <100 kg receive the 80 mg tablet once daily. Those at or above 100 kg receive 100 mg once daily 2. The FDA label allows dosing with or without food.

Step-by-Step Prescription Process in Florida

Getting Rezdiffra filled involves clinical confirmation, a prescription, coverage review when insurance is used, and a dispensing pharmacy. The sequence and time are not predictable enough to promise a two-to-three-week result.

Step 1: Establish Care with a Qualified Provider

Florida law does not make Rezdiffra a controlled substance, but the practical prescriber is usually a clinician comfortable documenting MASH/NASH fibrosis staging and managing hepatology follow-up. Hepatologists and gastroenterologists have the most familiarity with this workflow; primary care prescribing should include appropriate staging documentation and specialist referral when the fibrosis status is uncertain 5.

Step 2: Obtain Required Baseline Labs

Depending on the existing record and clinical question, the clinician may review or order:

• Comprehensive metabolic panel (CMP) with ALT, AST, and bilirubin
• Medication review for statins, CYP2C8 inhibitors, and other interaction concerns
• FibroScan or MRE for fibrosis staging
• Lipid panel (provides baseline for monitoring LDL reduction)
• Other testing when indicated by history, concomitant medicines, or diagnostic uncertainty

The FDA label advises monitoring for hepatotoxicity and gallbladder-related adverse reactions during treatment 2. AASLD guidance supports serial non-invasive assessment when following patients with NAFLD/MASLD fibrosis 5.

Step 3: Prior Authorization Submission

When a plan requires prior authorization, its current criteria may ask for some combination of:

• Confirmed MASH diagnosis (ICD-10 K75.81)
• Fibrosis stage F2 or F3 via FibroScan, MRE, or biopsy report
• BMI and metabolic comorbidity documentation
• Documentation that treatment will be used with diet and exercise
• Baseline LFT values

Turnaround time for PA decisions varies by insurer and whether the submitted fibrosis documentation is complete.

Step 4: Pharmacy Fill

Once approved, prescriptions usually route to a specialty pharmacy or the dispensing pharmacy specified by the patient's plan. Patients should verify current network requirements before assuming a particular pharmacy can fill the prescription.

Telehealth Access in Florida

Florida statute 456.47 permits telehealth prescribing when the standard of care is met 8. Rezdiffra is not a controlled substance, but telehealth still has a practical limitation: the clinician must be able to verify the diagnosis and fibrosis stage from records, labs, imaging, or biopsy.

How Telehealth Visits Work for Rezdiffra

A telehealth consultation should allow enough time to review the history, fibrosis evidence, laboratory data, medications, risks, and alternatives. Visit length and required uploads vary by provider. A telehealth visit does not guarantee that a prescription will be issued.

Telehealth Limitations

Telehealth providers cannot perform a FibroScan remotely. If staging is not already documented, you may still need in-person elastography, MRE, laboratory testing, or biopsy review before the prescription is appropriate 4, 5.

Florida Medicaid and Insurance Coverage

Florida Medicaid and marketplace plans can change formulary and prior-authorization criteria. Patients should check the current plan formulary or ask the prescriber's office to submit a benefits investigation rather than relying on a fixed statewide coverage promise.

Commercial Insurance in Florida

Commercial payers commonly ask for documentation of the labeled diagnosis, fibrosis stage, absence of decompensated cirrhosis, and use alongside diet and exercise. The exact rule set is plan-specific and should be checked before the first fill 2.

Cost Without Insurance

Out-of-pocket cost depends on insurance design, deductible status, prior authorization, and any manufacturer support available at the time of prescribing. Patients should confirm current terms directly through Madrigal's patient-support program or their insurer before making treatment decisions 9.

Compounded Resmetirom: Why to Be Careful

Rezdiffra is an FDA-approved oral tablet with a specific labeled dose and manufacturer. Do not assume that a compounded product marketed as resmetirom is therapeutically equivalent to Rezdiffra or covered by the same safety, efficacy, and manufacturing review.

Regulatory Framework

FDA compounding guidance distinguishes compounded drugs from FDA-approved drugs and warns that compounded drugs are not FDA-approved for safety, effectiveness, or quality before marketing 10. A patient considering any non-approved version should ask the prescriber and pharmacist to document why the FDA-approved product cannot be used.

Shipping Within Florida

If a pharmacy offers compounded resmetirom, verify the legal basis, ingredient source, testing, and prescriber rationale before paying. For most patients seeking labeled MASH therapy, the evidence-backed pathway is the FDA-approved Rezdiffra product.

Safety Monitoring and Follow-Up

The FDA label specifies safety risks that Florida providers should monitor during Rezdiffra therapy 2.

Liver Function Tests

Check liver tests at baseline and repeat them according to the prescriber's risk assessment, especially if symptoms such as fatigue, nausea, jaundice, dark urine, or right-upper-quadrant pain develop. The label warns about hepatotoxicity and recommends discontinuing Rezdiffra if hepatotoxicity is suspected 2.

Thyroid Monitoring

Because resmetirom is a thyroid hormone receptor beta agonist, clinicians should review thyroid history and medications before prescribing. Thyroid laboratory monitoring should be individualized rather than treated as a fixed universal schedule.

Gallbladder Events

The FDA label reports gallstone-related adverse reactions, including cholelithiasis and cholecystitis, and advises evaluation if symptoms occur 2.

Transferring a Prescription to Florida

An active non-controlled prescription may be transferable, but the sending and receiving pharmacies, remaining refills, prescriber authority, plan network, and current Florida rules determine the result. Confirm with both pharmacies before relying on a transfer.

Transfer Process

Your current pharmacy or specialty pharmacy can explain whether the prescription can be transferred or whether the receiving Florida clinician needs to issue a new prescription. Specialty-drug transfers depend on state rules, plan network requirements, and the dispensing pharmacy's policies.

New Patient Establishment

If you are establishing care with a new Florida provider, they may request updated records or testing before continuing the prescription. The need for repeat elastography or other assessment depends on the age and quality of existing evidence and whether a new result would change management 5.

Timeline: From First Visit to First Dose

An illustrative sequence, without fixed day promises, is:

1. Initial consultation in person or by eligible telehealth.
2. Records and fibrosis evidence reviewed; additional tests only if needed.
3. Prescribing decision after diagnosis, risks, interactions, and alternatives are assessed.
4. Benefits investigation or prior authorization if the plan requires it.
5. Pharmacy fill or shipment through the plan's eligible network.

If prior authorization is delayed, ask the prescriber's office whether current manufacturer support or pharmacy coordination options apply; do not assume bridge supply availability without checking the active program terms 9.

Drug Interactions Relevant to Florida Patients

Resmetirom has clinically important interaction considerations, especially with CYP2C8 inhibitors and some statins 2.

Key Interactions

• Strong CYP2C8 inhibitors (gemfibrozil): Avoid concomitant use; increases resmetirom exposure
• Strong or moderate CYP2C8 inhibitors: avoid or adjust according to the label, depending on the inhibitor
• Statins: follow the label's statin dose limits and monitor for statin-related adverse effects

Given that MASH patients frequently take cardiometabolic medications, a medication reconciliation is part of safe prescribing rather than a formality.

Long-Term Outlook and Confirmatory Trial

Rezdiffra received accelerated approval, meaning continued approval may depend on confirmatory clinical benefit. The MAESTRO-NASH outcomes study (NCT05761406) is evaluating progression to cirrhosis and other liver-related outcomes 11. Patients currently on therapy should continue as prescribed unless their provider advises otherwise based on safety, tolerability, or updated evidence.